Have you or your loved ones been diagnosed with solid tumors?

You may be eligible to participate in a solid tumors clinical trial.

Have you or your loved ones been diagnosed with solid tumors? You may be eligible to participate in a solid tumors clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Solid Tumors Clinical Trial in Austin TX
NCT02587598 | Phase 1 phase 2 | Interventional
Incyte Corporation
Sponsored by
Incyte Corporation

Have you or your loved ones been diagnosed with solid tumors?

You may be eligible to participate in a solid tumors clinical trial.

Have you or your loved ones been diagnosed with solid tumors? You may be eligible to participate in a solid tumors clinical trial.

Terminated

Male & Female

18 Years +

This study has recruited 97 Participants

This is an open-label, dose-escalation study of the proviral integration site of Moloney murine leukemia virus (PIM) kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 4 parts. Part 1 (monotherapy dose escalation) will evaluate safety and determine the maximum tolerated dose of INCB053914 monotherapy and the recommended phase 2 dose(s) (a tolerated pharmacologically active dose that will be taken forward into the remaining parts of the study). Part 2 (monotherapy dose expansion) will further evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of the recommended Phase 2 dose(s). Part 3 (combination dose finding) will evaluate safety of INCB053914 in combination with select standard of care (SOC) agents and will identify the optimal INCB053914 dose in combination with conventional SOC regimens to take forward into Part 4. Part 4 (combination dose expansion) will further evaluate the safety, efficacy and pharmacokinetics of the recommended Phase 2 dose combination(s).